Objective: Malignant cells in the pleural fluid or pleural metastases are now classified stage IV in lung cancer and alter the treatment. Our purpose was to question the role of surgery in such patients. Methods: The clinical records of 4668 patients, who underwent lung cancer surgery, were reviewed. In some, an undiagnosed pleural malignant disease (M1a) was discovered during thoracotomy. When feasible, selected patients underwent complete surgical resection of the primary tumor and pleural nodules. We analyzed the epidemiology, pathology, and prognosis characteristics of that group (study group), as compared with the population undergoing pulmonary resection in a curative attempt (overall population) or exploratory thoracotomy in case of unexpected disseminated carcinomatous pleuritis (control group). Results: The study group included 32 patients (25 males), mean age 59 AE 8.8 years, who underwent pneumonectomy (n = 9) or lobectomy (n = 23), associated with mediastinal lymph nodes dissection and surgical resection of associated pleural nodules. There were 21 adenocarcinomas, seven squamous cell carcinomas, two undifferentiated large cell carcinomas, and two miscellaneous tumors. Pathological node (pN) was: N0 in 10 patients (31.3%), N1 in four (12.5%), and N2 in 18 (56.3%). Five-year survival rate was 16% after resection, and 21% if the resection was a lobectomy. Conclusion: Complete surgical resection of non-small-cell lung cancer (NSCLC) associated with limited metastatic pleural involvement is associated with longterm survival in 16% of the cases. A review of the published data, together with the results of this series, may justify the inclusion of surgery in multimodality treatment of NSCLC patients with metastatic pleural extension. #
Introduction
Metastatic pleural extension of non-small-cell lung cancer (NSCLC) includes limited and localized pleural nodules defining limited metastatic pleural extension; numerous and disseminated nodules defining pleural carcinomatosis; and malignant cells in the pleural fluid defining malignant pleural effusion [1] .
The finding of metastatic pleural extension is reported in 1-7% of patients with NSCLC, and the pleura is affected in up to 10% of patients with metastatic disease [2, 3] . Such findings alter the prognosis, staging, and treatment of that large group of patients. In this group, median survival is 5-8 months, 5-year survival rates are 2-4% [2, 3] , tumor, node, metastasis (TNM) classification is M1a [4, 5] , and surgical resection is precluded.
However, metastatic pleural extension represents a wide range of situations. Among them, unexpected observation of localized pleural nodules during thoracotomy constitutes a situation where complete surgical resection may be proposed. The outcome of such patients is unknown. The purpose of our study was to question again the role surgery might play in NSCLC patients with metastatic pleural extension limited to localized and resectable pleural nodules.
Patients and methods

Patients
The clinical records of patients with NSCLC, who underwent thoracotomy on a curative attempt in Hôpital Européen Georges Pompidou (Paris) and Centre Chirurgical du Cêdre (Boisguillaume) between January 1983 and December 2006, were reviewed. Preoperative work-up included chest X-ray, bronchoscopy, computed tomography (CT) scan of the chest, spirometry, lung perfusion scan, and a thorough search for distant metastases, including positron emission tomography (PET) scan in recent years and mediastinoscopy in case of mediastinal extension suspicion. Preoperative discovery of multiple non-resectable distant metastases, N3 disease, and pericardial or pleural dissemination precluded surgery.
Preoperative pathologic identification of N2 disease was managed by preoperative chemotherapy, preoperative chemoradiation, first-line surgery followed by adjuvant treatment, or definitive chemoradiation, according to the number of stations involved, the size of adenopathies, the protocol applied by each referral center, and the period concerned. Postoperatively, adjuvant treatment was given to patient with acceptable performance status and pT3/T4 extension, pN2, or incomplete resection. During this period, 4668 patients underwent thoracotomy on a curative attempt, and account for the overall population.
Control and study group
Patients with previously undiagnosed pleural malignant metastatic disease (M1a) were evaluated for complete surgical resection. Cases of unexpected pleural metastatic extension were divided into two groups. If pleural extension was widespread as a diffuse non-resectable carcinomatous pleuritis, pleural biopsy alone was performed, and these patients were included in the control group. If pleural extension was limited to a small number of pleural nodules, complete surgical resection of primary tumor, mediastinal lymph nodes, and pleural metastatic nodules was decided, and these patients were included in the study group.
Staging system
The staging system was the International Staging System for NSCLC adopted in 1997 [4] , and recently modified concerning the T and M [5] . M1 NSCLCs are classified stage IV in both systems, but M1 is now subdivided into M1a: separate tumor nodule(s) in a contralateral lobe tumor with pleural nodules or malignant pleural (or pericardial) effusion, and M1b: distant metastases. For mediastinal-lymph-node involvement, the classification of Mountain and Dresler [6] was used.
Methods
The study was approved by our Thoracic Surgery Society Ethic Committee that waived the need for informed consent. For the three groups (overall population, control group, and study group), the following outcome variables were depicted and analyzed: gender, age, type of surgical resection, histology, T, type of nodal involvement, and R (resection) (R2 being gross tumor left behind, R1 marginal microscopic invasion, and R0 complete resection). Follow-up information was obtained from the hospital case records, from a questionnaire completed by the chest physician or general practitioner, or from death certificates. Postoperative death was defined as death occurring during the first 90 days, or during initial hospital stay, if longer. The main outcome was the overall survival, defined as the time interval between the date of operation and the date of death or the last follow-up visit for censored patients.
Statistical analysis
Normally distributed continuous variables were expressed as means AE standard deviation. Data from the three groups have been presented aside, but no direct statistical comparison has been performed. Categorical data were expressed as counts and proportions. Survival was depicted with the Kaplan-Meier estimate, and compared with log rank test. Uni-and multivariate analyses were performed using the Cox proportional hazards model for overall survival analysis. A probability value of P < 0.05 was considered significant. The statistical software used for the analysis was SEM (Anticancer Centre Jean Perrin, Clermont-Ferrand, France) [7] .
Results
Overall population
The overall population included a vast majority of males (82.5%), with smoking habits (90.1%), and a mean age of 61.4 (AE10.1) years. Induction therapy was infrequent (15%). The surgical resection included a lobectomy in 57% and a pneumonectomy in 36% of the cases. The rate of postoperative death was 4.4%, and surgical complications occurred in 26.5% of the cases. Pathological examination revealed a majority of squamous cell carcinoma (46%) and adenocarcinoma (38%). Tumor extension required classification as pT1 in 26.2%, pT2 in 50.3%, pT3 in 16%, and pT4 in 3.1% of the patients. Twenty-seven percent of the tumors presented with mediastinal nodal extension classified as N2 disease. Complete resection was obtained in 89.4% of the cases. Forty-one percent of the patients underwent adjuvant therapy, either with chemotherapy or ionizing radiations (Tables 1 and 2 ).
Study group
All together, 70 patients presented a pleural extension classified as M1a disease. Among them, 38 patients presented disseminated pleural carcinomatosis that necessitated pleural biopsy without parenchymatous resection, and accounted for the control group. The other 32 patients presented a pleural extension limited to a small number of pleural nodules that underwent complete surgical resection of primary tumor, mediastinal lymph nodes, and pleural metastatic nodules, and accounted for the study group. In the study group, the majority of patient underwent a lobectomy (72%) for an adenocarcinoma (66%), with pT2 (56%) and pN2 (56%) extension. Surgical resection was of the primary tumor, related lymphadenopathy, and pleural nodules were considered complete in all cases. Adjuvant therapy was performed in most of the cases (72%) ( Tables 1  and 2 ).
Outcome
The mean follow-up period was 72.8 (AE48) months for the overall population. Sixty-five patients (1.3% of the overall population) were lost during follow-up, but none belonged to the control and study groups. In the study group, the postoperative course was associated with a morbidity of 34% and a mortality of 16% ( Table 2 ). The median survival was 15 months. The 5-year survival rate was 16.2% (95% confidence interval (CI) 6.9-33.6) in the whole group. If the resection was a lobectomy or if the nodal status was N0, 5-year survival rates were 20.9% and 34.6%, respectively (Fig. 1) . As a comparison, no patients was alive after 5-year in the control group. The causes of death in the three groups are described in Table 3 .
Prognostic factors
After exclusion of the five patients who died during initial hospitalization, 27 patients from the study group were included in the prognosis analysis. No factors were significantly associated with overall survival in this limited group of patients, but a trend toward better survival was observed in patients undergoing adjuvant treatment (5-year survival rate, 22% vs 0%, P = 0.067) ( Table 4 ).
Discussion
The M1a patients represent 7.5% of NSCLC [3] , and 17-56% of malignant pleural effusions are due to lung cancer [8] . However, among the 7-15% patients with lung cancer diagnosed as having a pleural effusion [8] , cytology is negative in almost 50% of cases: the pleural effusion is nonmalignant, reactive [9] , surgery is not contraindicated, and the 5-year survival rate following surgery is similar to the one observed without pleural effusion [10] . On the other hand, malignant pleural effusion and/or nodular pleural involvement are contraindication for surgery, but they cannot always be diagnosed before operation. Thus, they may be a cause of exploratory thoracotomy without 5-year survival, but they may be also resectable and resected, with a 5-year survival rate of 16% as we observed, which suggests that operation must not be discouraged. Reyes and colleagues [11] were the first to report some success after operation. Out of 20 patients in whom malignant pleural effusion developed without evidence of disease outside the hemithorax, 10 received systemic combination chemotherapy with the longest survival being 21 months, six received chemotherapy and then had pleuropneumonectomy with a median survival of 19 months (postoperatively), and four had pleuropneumonectomy as an initial treatment with one patient surviving 59 months. Reyes and colleagues suggested that the most logical therapeutic approach to treating NSCLC with malignant pleural effusion should be to begin with systemic chemotherapy, followed by extrapleural pneumonectomy in case of responsiveness. In 1994, Akaogi and colleagues [12] reported 23 patients, who underwent either pleuropneumonectomy (n = 16) or limited resection (n = 7) followed by introduction of mitomycin C into the pleural cavity at the closing of the thoracotomy in all patients, and irradiation to the mediastinum in three and cisplatin-based chemotherapy in four postoperatively. The longest survival time was 42 months and the median survival time for patients who underwent pleuropneumonectomy without N2 involvement was 24 months. During the 1990s, other authors reported some 5-year survivors following surgery associated with different other treatment modalities, in that rare but challenging subset of patients. Yokoi and Miyazawa [13] published the 5-year survival of a woman, who underwent pleuropneumonectomy and postoperative cisplatin-based chemotherapy for a T2N0 adenocarcinoma. Shimizu and colleagues [14] reviewed 40 patients, among whom two underwent an exploratory thoracotomy; 10, a pleuropneumonectomy; and 28, a limited resection. Better results were observed after limited operation with one patient surviving 65 months, supporting the idea that local excision plus pleurectomy is justified in patients with NSCLC accompanied by pleural dissemination. These authors confirmed their results in 2000 [15] . We list some articles published from 2000 to 2002 in Table 5 [15] [16] [17] [18] [19] . No 5-year survival was observed in case of exploratory thoracotomy without resection [15] [16] [17] [18] ; best results following resection were observed in case of adenocarcinoma [15, 16] and in N0 patients [16, 17, 19] , as we also observed. Sawabata and colleagues [18] reported 5-year survival rates of 9% and 10% following resection, but estimated that such a result were not sufficiently beneficial for the survival of patients. They concluded that a trial of multimodality treatment was warranted for NSCLC patients with malignant effusion. We agree with this conclusion and suggest that such trials should apply not only to pleural malignancy diagnosed during work-up, but also to unsuspected malignancy discovered at thoracotomy. Malignant pleural effusion is effectively something special. It was considered a T4 (stage IIIB) lesion in the 1985 and 1997 revision, but many clinicians approached stage IIIB disease with pleural effusion-like stage IV disease and Green and colleagues [20] suggested to modify the classification. However, malignant pleural effusion is a particular entity, which was noticed by Mott and Sharma [21] , who suggested it should be given a distinct classification of stage IVA. All patients with M1 disease would be at stage IVB, which would identify the subtle differences between these two groups, and streamline clinical trials [21] . This point of view was adopted by the new TNM classification. The rationale for advocating multimodality treatment including surgery in case of M1a pleural involvement is not only supported by literature and personal experience, but also by the particular mode of lung cancer spread that represent the pleura. NSCLC tumor cells may be present in the pleural space without pleural involvement and are overlooked, except when detected by pleural-lavage cytology. Positive pleural-lavage-cytology frequency may vary from one publication to another, but average 5.8% of patients in an international individual patient data meta-analysis collecting 8763 patients [22] . It proved to be an independent predictor of adverse survival, suggesting it be appropriate to upstage patients by one T category and to consider it in all patients with NSCLC suitable for resection. We hypothesize that positive pleural-lavage cytology is the first stage of M1a malignant pleural effusion. Both stages exhibit a high frequency of adenocarcinomas and of mediastinal-lymphnode involvement, the latter being particularly increased in case of M1a. The pleura may play a particular role in peripheral NSCLC tumoral spread outside the lung [23] , a role similar to that which intrapulmonary nodes play within the lung. Positive pleural cytology with N2 should be an equivalence of 'skipping' metastasis, and M1a pleural nodules, an equivalence of N1 disease. Preformed stomas connect the subpleural lymphatics of the parietal and diaphragmatic pleura with the pleural space and drain the exfoliated tumor cells of peripheral NSCLC toward the mediastinal lymph nodes and/or the blood circulation.
Whether the dissemination of NSCLC to the pleura is based on systemic bloodstream dissemination or local extension remains unknown. In our study, the fact that only a minority of tumor (37%) with resectable M1a disease presented with a direct pleural invasion is a strong argument for the bloodbased, and not pleural-based, dissemination of tumor cells from the primary tumor to the pleura. On the contrary, the fact that patients with resectable M1a disease have a specific mortality closer to overall population with resectable M0 disease than to the control group with non-resectable M1a disease, argues for the classification of resectable M1a disease in locally advanced rather than metastatic disease. This discussion is also confounded by the subjective surgical assessment of the difference between limited and resectable pleural extension on the one hand, and disseminated and non-resectable pleural extension on the other hand, pointing to a major limitation of the current study.
All together, these data explain that despite the poor prognosis of intrapleural tumor cell seeding, pleural involvement can remain a localized disease in N0M0 patients and justify M1a NSCLC surgery inclusion in multimodality treatment. This should concern patient selection limited to clinical T1-2N0M0. Physicians and oncologists must be aware of this possibility of surgery as neo-adjuvant and/or adjuvant therapy, and not just consider it for drainage of the pleural effusion and pleurodesis with sclerosing agents.
Conclusion
In this study, complete surgical resection of NSCLC associated with limited metastatic pleural involvement is associated with long-term survival in 16% of the cases. Our results warrant additional studies to confirm the possible benefits of surgery in this subgroup of NSCLC patients, and to justify the inclusion of surgery in multimodality treatment of NSCLC patients with metastatic pleural extension.
